Pfizer Oncology strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. Our core areas of interest include: Tumor Cell Biology; Precision Medicine; Tumor Targeted Therapeutics; and Immuno-Oncology. In addition, our Integrative Biotechnology Group supports novel target identification and validation through functional genomics, proteomics, and other “omic” approaches.
We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:
- Breast, prostate, lung, bladder, colorectal, renal, melanoma and hematologic cancers
Specific areas of interest include:
- Oncogenic drivers and signaling pathways
- Epigenetics
- Hormone signaling
- Synthetic lethality
- Selective protein degraders
- Transcriptional regulators
- Immune modulators
- Immune cell engagers
- Precision medicine
- Functional genomics
- Liquid biopsy and imaging technologies
- In vivo cell reprogramming
Immuno-Oncology
The clinical successes reported with cancer immunotherapy are reshaping the field of oncology. Pfizer is significantly advancing activity in this area by partnering to
develop cutting edge science beyond the current mainstream immune checkpoints. The IO programs at Pfizer uniquely leverage a combination of our scientific and clinical strength in immunobiology, as well as our historical expertise in developing first-in-class cancer therapies.
Pfizer’s efforts in IO include external collaborative alliances with leading academic medical centers and visionary biotech firms. Our IO efforts are driven primarily by the Cancer Immunology Discovery Unit (CID) within our La Jolla, CA-based laboratory site. Leveraging its strength in biotherapeutics, along with core expertise in immunobiology, CID has a strong record of converting validated targets into novel protein-based therapeutics and advancing molecular and cell-based IO treatments. We would like to partner in the IO space on pre-clinical and clinical-stage immunomodulatory opportunities, with an emphasis on those agents that directly engage or impact T-cell and other tumor-infiltrating immune cell populations.
We are interested in establishing alliances to develop and access:
- Novel Targets for Overcoming Tumor-associated Immune Resistance
- Targets that impact the immune response to cancer cells; innate immune activation; and immuno-suppression
- Platform Technologies
- Mechanisms, biomarkers, and screening approaches to identify and accelerate the most promising combination therapies
- New modalities to promote immune responses: Bi-specific and Tri-specific antibody/cytokine platforms, nanoparticles, or novel T cell receptors (TCRs)
- Identification of new immune-modulating targets
- Monitoring of biomarkers of immune-responsiveness and immune-suppression within tumors
- Novel animal models that recapitulate more faithfully human tumor-immune system interactions
Not actively seeking partnering opportunities in:
- Antisense/siRNA/shRNA therapeutics
- Reformulated cytotoxic agents